Icon shares rise 7.4% after Medpace results; IQVIA up 1.8%

Icon shares rise 7.4% after Medpace results; IQVIA up 1.8%

Icon shares rose 7.4% following Medpace Holdings' earnings report, while IQVIA climbed 1.8%. The positive performance for Medpace came despite a 3.6% retracement in its share price over the past week. Over the last five years, Medpace's stock has seen a significant increase of 195%, with earnings per share (EPS) growing at an annual rate of 37% [1]. However, recent market sentiment has been cautious, as indicated by the 9.1% EPS growth forecast for the upcoming Q2 earnings report, which is slightly below the 24% average annual increase in the share price [2].

IQVIA, on the other hand, saw its stock price rise following its Q2 earnings preview. The consensus EPS estimate was $2.77, a 4.9% year-over-year increase, and the revenue estimate was $3.96 billion, marking a 3.9% growth [3]. IQVIA has a strong track record of beating EPS and revenue estimates, with a 100% and 88% success rate, respectively, over the last two years [3].

Insider activity also played a role in the market's perception of these companies. Medpace's insiders have been active buyers, with the Vickers Top Insider Picks identifying the company as having compelling insider purchase histories [4]. Meanwhile, Kymera, a clinical-stage biotechnology company, saw its stock surge 70.7% over the past three months, driven by a recent collaboration with Gilead Sciences [5].

References:
[1] https://finance.yahoo.com/news/medpace-holdings-nasdaq-medp-earnings-122745017.html
[2] https://www.gurufocus.com/news/2989099/medpace-medp-set-to-release-q2-earnings-analysts-anticipate-eps-growth
[3] https://seekingalpha.com/news/4469415-iqvia-q2-2025-earnings-preview
[4] https://finance.yahoo.com/sectors/healthcare/biotechnology/
[5] https://www.nasdaq.com/articles/kymera-surges-70-3-months-buy-sell-or-hold-stock